We present 2 cases of Mycoplasma genitalium infection that were successfully treated with moxifloxacin despite the presence of quinolone resistance–associated mutations in these strains.
We evaluated the ResistancePlus® MG assay in providing macrolide resistance-guided treatment (RGT) for Mycoplasma genitalium infection at a UK sexual health centre. M. genitalium–positive samples from men with urethritis and women with pelvic inflammatory disease (PID) were tested for macrolide resistance–mediating mutations (MRMMs). MRMM-positive infections were given moxifloxacin 400 mg; otherwise 2 g azithromycin (1 g single dose and then 500 mg OD) was given. Among 57 M. genitalium–positive patients (32 men and 25 women), MRMMs were detected in 41/57 (72% [95% confidence interval (95% CI) 58–83%). Thirty-two of 43 patients given RGT attended for test of cure. Treatment failure rate was significantly lower at 1/32 (3%) than 10/37 (27%) before RGT ( n = 37 [men = 23 and women = 17]; p = 0.008). Treatment failure was lower in male urethritis (0/15 vs. 7/21 p = 0.027) but not in female PID. There was a trend of a shorter time to negative test of cure (TOC) in male urethritis (55.1 [95% 43.7–66.4] vs. 85.1 [95% CI CI 64.1–106.0] days, p = 0.077) but not in female PID. Macrolide resistance is higher than previous UK reports and higher than expected. RGT reduces overall treatment failure and is particularly beneficial in M. genitalium urethritis. Fluoroquinolone resistance will continue to rise with increasing fluoroquinolone use, and RGT is critical to direct appropriate azithromycin use and prevent overuse of moxifloxacin.
Background The occurrence of azithromycin resistance in M. genitalium infection is unknown in Africa, where diagnostic resources are limited and STIs are managed syndromically. This study aims to gain insight in the molecular epidemiology including antimicrobial resistance of M. genitalium infection in South Africa. Methods We collected 87 M. genitalium-positive samples obtained from participants in three study cohorts: HIVinfected pregnant women residing in townships in Pretoria (n=44), men and women accessing primary healthcare services in rural Mopani District (n=32), and men accessing sexual health services in Johannesburg (n=11). Molecular typing was performed using single nucleotide polymorphism (SNP) analysis of the MG191 gene to determine sequence type (ST) combined with variable-number of tandem-repeat (VNTR) assessment of the MG309 gene. Molecular detection of macrolide resistance-associated mutations in the 23S rRNA gene was done and, if detected, subsequent sequencing of the parC and gyrA genes for quinolone resistance. Results SNP analysis was successful in 22 specimens and showed 17 different STs (9 known and 8 new STs). VNTR assessment was successful for 36 specimens and showed variation in the number of repeat, ranging from 8 to 19; four strains had the same number of repeats (11). There was no geographic clustering of specific STs or number of repeats observed. Azithromycin resistance was detected in only 1/87 specimens (1.1%); a mutation in the parC gene associated with quinolone resistance was also detected in this case. This specific strain was a unique novel ST, but with similar tandem repeats, compared to the drug-susceptible stains. Conclusion This study shows a well-established, genetically diverse epidemic of M. genitalium infection in South Africa. The prevalence of azithromycin resistance was low, which is probably the result of the relatively recent introduction of azithromycin in the syndromic management guidelines. Nevertheless, introduction of diagnostics and surveillance of resistance is urgently warranted. Disclosure No significant relationships.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.